Legend Biotech CEO to Present Latest Updates at J.P. Morgan Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: Globenewswire
- Conference Announcement: Legend Biotech's CEO, Dr. Ying Huang, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026, at 9:00 AM PT, which is expected to attract attention from investors and other stakeholders.
- Live Webcast: The presentation will be available via a live webcast on Legend's Investor Relations page, with a replay accessible approximately 48 hours post-event, ensuring that investors unable to attend live can still access critical information.
- Company Scale: With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company, focusing on innovations that transform cancer care, particularly in the CAR-T cell therapy sector.
- Product Development: The company's CARVYKTI®, developed in collaboration with Johnson & Johnson as a one-time treatment for relapsed or refractory multiple myeloma, showcases its leadership in cell therapy and positions it to drive further innovations in its pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LEGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LEGN
Wall Street analysts forecast LEGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEGN is 68.10 USD with a low forecast of 48.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.720
Low
48.00
Averages
68.10
High
90.00
Current: 17.720
Low
48.00
Averages
68.10
High
90.00
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Deutsche Bank Downgrades Qiagen to Hold, Raises Price Target to $54
- Qiagen Rating Change: Deutsche Bank analyst Jan Koch downgraded Qiagen N.V. (NYSE:QGEN) from Buy to Hold while raising the price target from $52 to $54, indicating a cautious outlook on the company's future growth prospects.
- Legend Biotech Downgrade: TD Cowen analyst Yaron Werber downgraded Legend Biotech Corp (NASDAQ:LEGN) from Buy to Hold and significantly cut the price target to $21, reflecting concerns about its market performance, even as the stock closed at $20.76 on Wednesday.
- Crocs Rating Adjustment: Keybanc analyst Ashley Owens downgraded Crocs Inc (NASDAQ:CROX) from Overweight to Sector Weight, suggesting diminished confidence in the brand's future growth potential, with shares closing at $85.27 on Wednesday.
- Zoetis Rating Change: Piper Sandler analyst David Westenberg downgraded Zoetis Inc (NYSE:ZTS) from Overweight to Neutral and lowered the price target from $190 to $135, reflecting concerns about its profitability, despite the stock closing at $125.08 on Wednesday.

Continue Reading
Johnson & Johnson Exceeds Earnings Expectations and Raises Forecast Despite Share Decline
- Earnings Report: Johnson & Johnson reported better-than-expected earnings for the fourth quarter.
- Stock Performance: Despite the positive earnings report, the company's stock was falling.

Continue Reading





